Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Encompass Health operates 158 inpatient rehabilitation hospitals across 37 states, making it the largest owner/operator of inpatient rehab facilities in the United States. The company treats patients recovering from strokes, brain injuries, spinal cord injuries, complex orthopedic conditions, and other debilitating illnesses through intensive therapy programs averaging 15-day lengths of stay. Stock performance is driven by patient admission volumes, Medicare reimbursement rate changes, and labor cost management in a tight healthcare staffing environment.
Encompass generates revenue through per-discharge payments from Medicare under the Inpatient Rehabilitation Facility Prospective Payment System (IRF-PPS), which reimburses based on patient case-mix complexity and geographic wage adjustments. Commercial payers typically reimburse at 150-200% of Medicare rates, providing significant margin uplift. The company's competitive advantage stems from scale-driven operating leverage (centralized clinical protocols, purchasing power, and recruitment infrastructure), regulatory barriers to entry (60% compliance rule requiring patients meet specific medical criteria), and Certificate of Need requirements in many states that limit new facility development. Pricing power is moderate - Medicare rates adjust annually based on CMS rulemaking (typically 2-3% increases), while commercial rates are negotiated with regional health plans.
Medicare reimbursement rate updates announced annually by CMS (typically October for following calendar year implementation) - 100-200 basis point changes materially impact margins
Same-store admission growth and discharge volumes - 3-5% organic growth drives earnings leverage
Labor cost inflation and nursing staff availability - contract labor usage vs full-time employee ratios directly impact margins by 200-300 basis points
De novo hospital ramp performance - new facilities reach breakeven in 18-24 months and mature profitability in 3-4 years
Commercial payer rate negotiations and managed care penetration trends
Medicare reimbursement policy changes - CMS could modify IRF-PPS payment methodology, tighten the 60% compliance rule, or shift reimbursement toward value-based models that pressure per-discharge rates. Budget reconciliation efforts periodically target post-acute care spending.
Site-of-care migration - increasing pressure from Medicare Advantage plans and ACOs to shift rehabilitation services to lower-cost settings (skilled nursing facilities, home health, outpatient therapy) could compress inpatient volumes despite clinical evidence supporting IRF outcomes for complex cases
Regulatory compliance risk - maintaining 60% rule compliance across all facilities is operationally intensive; violations result in loss of IRF designation and reimbursement downgrades to lower acute care hospital rates
Hospital system competition - large health systems (HCA, Tenet, regional nonprofits) operate competing inpatient rehab units and may leverage integrated networks to retain post-acute patients rather than referring to Encompass facilities
Labor market competition - intense competition for physical therapists, occupational therapists, and rehabilitation nurses with national staffing agencies and hospital systems, driving wage inflation and contract labor dependency during shortages
Minimal leverage risk given 0.08x Debt/Equity ratio and strong interest coverage, though $700M annual capex requirements (new hospitals, maintenance, IT infrastructure) consume 60% of operating cash flow
Professional and general liability insurance exposure - medical malpractice claims and regulatory investigations create contingent liabilities, though historically well-managed through captive insurance structures
low - Healthcare utilization, particularly post-acute rehabilitation, is relatively non-discretionary and driven by medical necessity rather than economic conditions. However, elective orthopedic procedures (joint replacements) that feed rehabilitation admissions show modest correlation to consumer confidence and employment levels. Medicare patient volumes (70% of mix) are demographically driven by aging population trends rather than GDP growth.
Moderate sensitivity through two channels: (1) Valuation multiple compression as rising rates make defensive healthcare stocks less attractive relative to risk-free yields - typically trades at 12-15x EBITDA, which contracts 1-2 turns when 10-year Treasury exceeds 4.5%. (2) Modest impact on expansion financing costs for new hospital development, though the company maintains low leverage (0.08x Debt/Equity) and generates strong operating cash flow ($1.2B annually) to self-fund most growth capex. Refinancing risk is minimal given conservative capital structure.
Minimal direct exposure. Revenue is primarily government-backed (Medicare/Medicaid) with minimal bad debt risk. Commercial insurance receivables are diversified across major national and regional payers. The company does not extend consumer credit. Credit market conditions affect valuation multiples and M&A financing availability for industry consolidation opportunities, but core operations are insulated from credit cycles.
growth - The company attracts growth-oriented healthcare investors seeking exposure to demographic tailwinds (aging population driving rehabilitation demand), consistent double-digit earnings growth (24% net income growth TTM), and strong returns on equity (22.6% ROE). The combination of 10%+ revenue growth, margin expansion potential, and capital deployment optionality (new hospital development, M&A, buybacks) appeals to investors willing to accept healthcare regulatory risk for above-market growth rates. Modest 3.9% FCF yield limits appeal to pure income investors.
moderate - Healthcare services stocks typically exhibit beta of 0.7-0.9 to broader markets, with company-specific volatility driven by quarterly volume trends, Medicare policy announcements, and labor cost surprises. Stock experiences 15-20% intra-year drawdowns during periods of reimbursement uncertainty or broader healthcare sector rotation, but defensive characteristics limit downside relative to cyclical sectors.
